

August 28, 2014

Dear Editor,

Please find enclosed the edited manuscript in Word format (file name: 12854-Review.doc).

Title: Targeted approaches for HER2 breast cancer therapy: news from nanomedicine?

Author: Serena Mazzucchelli, Marta Truffi, Luisa Fiandra, Luca Sorrentino and Fabio R Corsi

Journal: *World Journal of Pharmacology*

ESPS Manuscript NO: 12854

The manuscript has been improved according to the suggestions of reviewers:

1 Format has been updated

2 Revision has been made according to the suggestions of the reviewer

(1) Typos were corrected as suggested by reviewer.

(2) It was pointed that Pertuzumab does not affect EGFR-HER2 dimer formation. Reviewer also ask to update the section about Neratinib, since he asserts that the phase III trial is just finished. After an extensive research in literature, we could not find any reference about the closure of the mentioned phase III clinical trial on Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2+ metastatic breast cancer. According to the last update (April 2014) of ClinicalTrials.gov this study (NCT01808573) is still ongoing, and it should be completed in May 2018 (<http://clinicaltrials.gov/show/NCT01808573>). However, we have added to the manuscript another recent clinical trial on administration of Neratinib in combination with Trastuzumab in HER2-positive metastatic breast cancer previously treated with anti-HER2 therapy, with interesting results.

3 References and typesetting were corrected

Thank you again for publishing our manuscript in the *World Journal of Pharmacology*.

Sincerely yours,



Fabio Ruggero CORSI, MD, Prof.

Surgery Division, "L. Sacco" University Hospital

Department of Clinical Sciences "L. Sacco"

Milan, 20157, Italy

Telephone: +39-02-39043449

Fax: +39-02-50319846

Email: Fabio.corsi@unimi.it